Comparative Pharmacology
Head-to-head clinical analysis: DOLUTEGRAVIR EMTRICITABINE AND TENOFOVIR ALAFENAMIDE versus EMTRICITABINE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DOLUTEGRAVIR EMTRICITABINE AND TENOFOVIR ALAFENAMIDE versus EMTRICITABINE.
DOLUTEGRAVIR, EMTRICITABINE and TENOFOVIR ALAFENAMIDE vs EMTRICITABINE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Dolutegravir is an HIV-1 integrase strand transfer inhibitor (INSTI) that blocks viral DNA integration. Emtricitabine is a nucleoside reverse transcriptase inhibitor (NRTI) that terminates viral DNA chain elongation. Tenofovir alafenamide is an NRTI that inhibits HIV reverse transcriptase after intracellular conversion to tenofovir diphosphate.
Nucleoside reverse transcriptase inhibitor; phosphorylated to emtricitabine triphosphate which competes with endogenous deoxycytidine triphosphate and incorporates into viral DNA causing chain termination.
One tablet (50 mg dolutegravir/200 mg emtricitabine/25 mg tenofovir alafenamide) taken orally once daily with or without food.
200 mg orally once daily, typically in combination with other antiretroviral agents.
None Documented
None Documented
Dolutegravir: ~14 hours (single dose), ~12 hours (steady state). Emtricitabine: ~10 hours. Tenofovir alafenamide: ~0.5 hours (parent), but its active metabolite tenofovir diphosphate has intracellular half-life >60 hours. Clinically, tenofovir alafenamide is dosed once daily due to intracellular accumulation.
Terminal elimination half-life is approximately 10 hours (range 8–12 hours) in adults with normal renal function; prolonged to >20 hours in severe renal impairment (CrCl <30 mL/min).
Dolutegravir: ~64% feces (as parent), ~31% urine (as glucuronide conjugate, <1% parent). Emtricitabine: ~86% urine (as parent and metabolites), ~14% feces. Tenofovir alafenamide: <1% renal (as parent), ~82% feces (as metabolite tenofovir).
Renal: approximately 86% of the dose is excreted unchanged in urine via glomerular filtration and active tubular secretion. Biliary/fecal: minimal (<14% as unchanged drug and metabolites in feces).
Category A/B
Category C
NRTI
Antiretroviral, NRTI